PHIO · ISSUER CIK 1533040
Phio Pharmaceuticals Corp.
Between Jul 31, 2026 and Oct 28, 2026, 4 Phio Pharmaceuticals Corp. insiders reported $59K of open-market purchases and $0.00 of sales on SEC Form 4. The largest buyer was Plott Ronald Todd (Director), with $27K.
↗4 insiders filed
Original Form 4 filings from Jul 31, 2026 to Oct 28, 2026. No open-market sales in the window.
$59KInsider buying
$0.00Insider selling
+$59KNet open-market
Sep 30, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 202616:01 | Sep 29, 2026from Sep 28, 2026 | PHIO | Director | P · Buy | $1.04 | +10,000 | 42,000 | +31% | +$10K | -14.5% | -11.4% |
| Sep 29, 202616:01 | Sep 28, 2026 | PHIO | Chief Financial Officer | A · Grant | — | +108,000 | 189,112 | +133% | — | ||
| Sep 29, 202616:01 | Sep 28, 2026 | PHIO | Chairman, Pres. & CEO, Director | A · Grant | — | +400,000 | 764,871 | +110% | — | ||
| Sep 29, 202616:01 | Sep 28, 2026 | PHIO | Director | A · Grant | — | +17,000 | 32,000 | +113% | — | ||
| Sep 25, 202616:01 | Sep 24, 2026 | PHIO | Director | P · Buy | $1.01 | +6,500 | 64,151 | +11% | +$7K | -16.3% | -9.4% |
| Sep 23, 202616:01 | Sep 22, 2026 | PHIO | Chairman, Pres. & CEO, Director | P · Buy | $1.03 | +2,000 | 364,871 | +1% | +$2K | -15.0% | -10.9% |
| Sep 16, 202616:01 | Sep 15, 2026 | PHIO | Director | P · Buy | $1.03 | +12,000 | 57,651 | +26% | +$12K | -14.9% | -11.0% |
| Sep 15, 202616:00 | Sep 11, 2026 | PHIO | Chief Financial Officer | F · Tax | $1.03 | −12,888 | 81,112 | -14% | $13K | ||
| Sep 15, 202616:00 | Sep 11, 2026 | PHIO | Chairman, Pres. & CEO, Director | F · Tax | $1.03 | −68,550 | 362,871 | -16% | $71K | ||
| Aug 20, 202608:30 | Aug 19, 2026 | PHIO | Director | P · Buy | $1.14 | +15,000 | 15,000 | New | +$17K | 0.0% | -19.6% |
| Aug 19, 202616:01 | Aug 18, 2026 | PHIO | Chairman, Pres. & CEO, Director | P · Buy | $1.06 | +10,000 | 431,421 | +2% | +$11K | -7.0% | -13.5% |